Topical bioelectric therapy for corneal repair

Persistent corneal epithelial defects are surface wounds that remain open despite supportive care. As closure stalls, patients can move from lubrication, antibiotics, and bandage contact lenses to serum tears, amniotic membrane, tarsorrhaphy, grafting, or transplant.

Galvanis is starting here because the treatment is local, the endpoint is visible, and time-to-closure can be measured directly.

• About 100,000 people per year are diagnosed with PCED in the U.S. That is large enough to matter clinically and small enough to fall below the 200,000 orphan-disease threshold. Orphan Drug and Fast Track designations both have precedent in this indication.

• Objective endpoint: complete epithelial closure by fluorescein imaging.

• When corneal defects fail to close, care escalates to procedures: amniotic membrane grafts, serum tears, tarsorrhaphy, and eventually transplant. These add cost, facility dependence, and patient morbidity. Sutureless ocular amniotic-membrane grafting alone grew from $3.5M to $95.6M in annual Medicare charges between 2011 and 2020, across all ocular indications.¹ GALVANIS aims to intervene earlier and topically, before patients reach that pathway.

• ¹ Total across all ocular indications (predominantly dry eye). Source: Utilization Patterns and Costs of Ocular Amniotic Membrane Grafts in the Medicare Population, Ophthalmology (2025).

When corneal defects do not close, care escalates